BioCentury
ARTICLE | Preclinical News

Selecta's rapamycin nanoparticles could enable re-dosing of gene therapies

October 5, 2018 9:52 PM UTC

Selecta Biosciences Inc. (NASDAQ:SELB) showed its SVP-Rapamycin nanoparticles co-administered with an adeno-associated viral (AAV) vector-mediated transgene could enable repeat dosing of a gene therapy by suppressing the host’s immune response against the viral vector in preclinical models.

While repeated administration of gene therapies may be necessary to ensure sustained therapeutic efficacy, immunogenicity against vector-mediated gene therapies limits follow-on dosing, as the host develops antibodies against the vector. Author and Selecta CSO Takashi Kei Kishimoto told BioCentury repeated administration is particularly needed in pediatric patients in which non-dividing vectors don't keep up with organ growth, leading to dilution of gene expression...